AUPH - Aurinia Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.21
-0.06 (-0.96%)
As of 10:01AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close6.27
Open6.27
Bid6.22 x 900
Ask6.24 x 2900
Day's Range6.23 - 6.38
52 Week Range5.01 - 7.85
Volume50,062
Avg. Volume1,058,513
Market Cap569.281M
Beta (3Y Monthly)0.42
PE Ratio (TTM)N/A
EPS (TTM)-0.63
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.92
Trade prices are not sourced from all markets
  • Big Pharma faces the Senate in drug price hearings
    Yahoo Finance Video20 days ago

    Big Pharma faces the Senate in drug price hearings

    Yahoo Finance's Adam Shapiro, Julie Hyman, Jessica Smith, and Brian Sozzi discuss the Pharma executives testifying in the Senate drug price hearings.

  • Business Wire4 days ago

    Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease

    In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a late clinical-stage biopharmaceutical company with research ongoing in two kidney diseases, Lupus Nephritis (LN) and Focal Segmental Glomerulosclerosis (FSGS), today announced a host of activities, including an initiative with The National Kidney Foundation (NKF), designed to raise awareness for kidney disease.

  • Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for
    Zacks6 days ago

    Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for

    Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire11 days ago

    Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019

    Aurinia Pharmaceuticals Inc. today announced that it will release its fourth quarter and full year 2018 financial results on Tuesday, March 19, 2019, after the market closes.

  • After Patent News, Aurinia Pharmaceuticals Still Has More to Prove
    InvestorPlace19 days ago

    After Patent News, Aurinia Pharmaceuticals Still Has More to Prove

    Aurinia Pharmaceuticals (NASDAQ:AUPH) leapt close to 20% on Monday. AUPH stock took off after the announcement of a new patent for the application method of its lupus nephritis drug.Source: Shutterstock This gave AUPH stock some much-needed excitement. Shares have languished between $5 and $6.50 for most of the past year, as investors await key clinical trial readouts. Bulls hope this patent news may finally break the gridlock and allow the stock to reach its highest levels in several years. However, Aurinia still has more work to do. Why The Patent News MattersThere was an interesting reaction with Aurinia stock after the news came out. At first, the stock didn't jump too much -- opening up just a few percent. But throughout the day, shares traded steadily higher as investors further considered the consequences.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 5 Clinical-Stage Biotech Stocks to Buy On the one hand, this is an important development for Aurinia. One of the lingering issues with Aurinia has been that the primary patents around its Voclosporin were initially set to expire in 2022.Normally, a biotech company has a much longer window to generate exclusive revenues from its products before generic competitors launch their own versions. Given that short window, bears have suggested that Aurinia would have issues profiting adequately when the drug comes to market.Aurinia had several options to deal with this issue. They already managed to use one regulatory pathway to get a five-year extension out of 2027. So that had reduced the investment risk substantially. Still, most clinical stage biotech companies have patent exclusivity much longer than eight years, so investors were right to price that in as a risk for AUPH stock.With this patent, Aurinia may have overcome this challenge. What Changed, And What Hasn'tOn Monday, Aurinia published a press release, stating:"Notably, the allowed claims cover a method of modifying the dose of voclosporin in patients with lupus nephritis (LN) based on patient specific pharmacodynamic parameters."The new patent on Voclosporin runs out through 2037, giving Aurinia excellent protection from generic competition.That said, reading carefully, we see that the patent covers modification of the dose of Voclosporin, not the actual drug itself. It's seemingly unclear if generics could still compete with Voclosporin as long as they use a different dosing method. And there's still another much bigger question to deal with first: Will the drug be approved? After all, a patent won't matter if the drug never makes it to market.The all-important Phase III trial is set to deliver results around the end of 2019. It's far from a given that Voclosporin will succeed and go on to obtain FDA approval. The company's previous trial ran into significant safety issues with patients dying during the study. Given the FDA's concerns on safety issues, investors should be careful about assuming approval before the definitive trial results come in.On top of that, in the previous trial, the company's lower dose version of the drug showed a stronger clinical effect than the higher dose version. Again, there is a plausible explanation for this: management suggests the higher dose version wasn't tolerated well in patients. Still, an inconsistent dose response is another caution flag for biotech trials.To summarize, while the patent news is a plus for AUPH stock, don't overlook the small matter that the drug still has to perform in its pivotal phase III trial and pick up FDA approval. AUPH Stock VerdictThe company does have a few other options beyond the key lupus trial. It is also testing Voclosporin for other conditions, such as dry eye. That program produced a mixed set of clinical results recently. It missed its key endpoint, but showed stronger efficacy than expected.It's unclear what exactly this will mean for the dry eye program going forward. In any case, phase III results are still a few years away. Additionally, there is much more competition in that market than there would be for lupus nephritis.So, despite the flurry of attention for dry eye that Aurinia proponents have shown, don't get distracted from the main event. The lupus results should be coming up within a year from now. Those results will determine whether or not AUPH stock delivers for its shareholders.Finally, I should note the unambiguously positive thing about Aurinia at this point: its strong fiscal position. As of the most recent quarter, it had $139 million in cash, and was burning ~$45 million annually. That gives it more than two years to keep advancing the clinical pipeline. * 7 IPOs to Get Excited for in 2019 On top of that, the company subsequently announced a $30 million stock offering, which will add a few more quarters worth of working cash to its already substantial treasury. While Aurinia's ultimate success is far from certain, they've got a respected management team and enough cash to give Voclosporin time to attempt to prove its potential.At the time of this writing, Ian Bezek held no positions in any of the aforementioned securities. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Consumer Stocks to Buy and Hold for Years * 4 China Stocks Soaring on Trade Hopes * 3 Esports Stocks to Benefit From the Boom Compare Brokers The post After Patent News, Aurinia Pharmaceuticals Still Has More to Prove appeared first on InvestorPlace.

  • Business Wire19 days ago

    Aurinia Closes At-The-Market Facility

    Aurinia Pharmaceuticals Inc. today announced that, further to its Open Market Sale Agreement with Jefferies LLC previously disclosed on November 30, 2018, in relation to at-the-market offerings of common shares in the capital of the Company, the Company has completed the sale of 4,608,409 common shares at a weighted average price of US$6.55 for aggregate gross proceeds of approximately US$30 million....

  • Here's Why Aurinia Pharmaceuticals' Stock Jumped Today
    Motley Fool21 days ago

    Here's Why Aurinia Pharmaceuticals' Stock Jumped Today

    It looks like an important patent that could protect its lead candidate is a done deal.

  • Business Wire21 days ago

    Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/ TSX:AUP) (the “Company” or “Aurinia”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for U.S. patent application 15/835,219, entitled “PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS”. The allowed claims broadly cover the novel voclosporin dosing protocol adhered to and required in both the previously reported Phase II AURA-LV study and the ongoing Phase III confirmatory AURORA study.

  • Business Wire26 days ago

    Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City

    Aurinia Pharmaceuticals Inc., today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference in NYC on February 27, 2019 at 2:30pm ET.

  • Is Aurinia Pharmaceuticals a Buy?
    Motley Fool2 months ago

    Is Aurinia Pharmaceuticals a Buy?

    The pharma company bounced around for much of 2018, but there's intriguing potential in the pipeline.

  • GlobeNewswire2 months ago

    Factors of Influence in 2019, Key Indicators and Opportunity within Leidos, Nomad Foods, Huron Consulting Group, Casella Waste, The Medicines, and Aurinia Pharmaceuticals — New Research Emphasizes Economic Growth

    NEW YORK, Jan. 30, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Benzinga2 months ago

    Aurinia's Dry Eye Syndrome Drug Produces Mixed Results In Mid-Stage Trial

    Small-cap biotech Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) fell Tuesday morning following the release of clinical trial results. What Happened Aurinia said a mid-stage study that evaluated its dry eye ...

  • Business Wire2 months ago

    Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive results for its exploratory Phase 2 head-to-head study evaluating the efficacy, safety and tolerability of voclosporin ophthalmic solution (VOS 0.2%) versus Restasis®(cyclosporine ophthalmic emulsion 0.05%) for the treatment of dry eye syndrome (DES). Both drugs were shown to be well-tolerated and there was no statistical difference between VOS and Restasis® for the primary endpoint as both drugs exhibited low drop discomfort scores.

  • Business Wire2 months ago

    Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it will report results before the opening of trading and hold a webcast and conference call to discuss the results of its Phase 2, double-masked, head-to-head study of VOS 0.2% versus Restasis® (cyclosporine ophthalmic emulsion 0.05%) to evaluate the efficacy, safety and tolerability at four weeks in subjects with dry eye syndrome (DES). Aurinia will host a conference call and webcast presentation at 8:00am ET on Tuesday, January 22, 2019.

  • Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?
    Zacks2 months ago

    Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?

    Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

  • TheStreet.com2 months ago

    My Rx for How to Buy Aurinia Pharmaceuticals on Its Breakout

    In Tuesday's fast-paced Lightning Round of Jim Cramer's "Mad Money" program on CNBC, Jim commented that Aurinia Pharmaceuticals Inc. was "a great speculative stock." Let's check out the charts to see what sort of potential AUPH may have in the months ahead. In this daily bar chart of AUPH, below, we can see that prices broke out on the upside from a year-long sideways consolidation pattern.

  • ACCESSWIRE3 months ago

    4 Pharma Stocks Getting a Boost on Thursday (12/20/18)

    CORAL GABLES, FL / ACCESSWIRE / December 20, 2018 / The healthcare industry is complicated, this much is certain, but amidst the complexities exist innovative approaches to healthcare that will ultimately provide the best quality of care for patients in the future. From advancements in the nascent telehealth industry to improved treatment options for patients, the healthcare sector may offer significant opportunities in the near future. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Aevi Genomic Medicine, Inc (GNMX), Aurinia Pharmaceuticals, Inc (AUPH), and CV Sciences, Inc (CVSI) are 4 pharma stocks to pay attention to heading into the rest of the week.

  • Business Wire3 months ago

    Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco

    Aurinia Pharmaceuticals Inc., today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a company overview at the 37th Annual J.P.

  • Business Wire4 months ago

    Aurinia Establishes at-the-Market Facility

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced that it has entered into an Open Market Sale Agreement (the “Sale Agreement”) with Jefferies LLC (“Jefferies”) pursuant to which the Company may from time to time sell, through at-the-market (“ATM”) offerings with Jefferies acting as sales agent or directly to Jefferies acting as principal, such common shares in the capital of the Company (“Common Shares”) as would have an aggregate offering price of up to US$30,000,000. Aurinia has also filed a prospectus supplement with securities regulatory authorities in Canada in the provinces of British Columbia, Alberta and Ontario, and with the United States Securities and Exchange Commission, which supplements Aurinia’s short form base shelf prospectus dated March 26, 2018, and Aurinia’s shelf registration statement on Form F-10 dated March 26, 2018, declared effective on March 29, 2018.

  • GlobeNewswire4 months ago

    Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire4 months ago

    Aurinia to Participate in November Investor Conferences

    Aurinia Pharmaceuticals Inc., today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences.

  • Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
    Zacks4 months ago

    Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates

    Aurinia (AUPH) delivered earnings and revenue surprises of -23.53% and 476.92%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press4 months ago

    Aurinia: 3Q Earnings Snapshot

    The Victoria, British Columbia-based company said it had a loss of 21 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Business Wire4 months ago

    Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development

    VICTORIA, British Columbia-- -- AURORA Phase III Trial in lupus nephritis completes enrollment ahead of schedule Phase II data for the treatment of dry eye expected in January 2019 Phase II FSGS Trial ongoing Richard M. Glickman announces his intention to retire as CEO next year, upon identification and appointment of an appropriate successor Aurinia Pharmaceuticals Inc. has released its financial ...

  • Business Wire5 months ago

    Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018

    Conference Call and webcast to follow